These mutations usually coexist with one of the three main driver mutations of MPN (i.e., JAK2, CALR, or MPL) [77], and the presence of certain additional mutations (e.g., ASXL1) has a powerful, adverse effect on clinical outcomes [78]. This evidence concerns the gene MPL and myeloproliferative neoplasm.